Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species by �씠寃쎌썝
ISSN 2234-3806 • eISSN 2234-3814 
190  www.annlabmed.org https://doi.org/10.3343/alm.2019.39.2.190
Ann Lab Med 2019;39:190-199
https://doi.org/10.3343/alm.2019.39.2.190
Original Article
Clinical Microbiology
Antimicrobial Susceptibility Patterns of Anaerobic 
Bacterial Clinical Isolates From 2014 to 2016, 
Including Recently Named or Renamed Species 
Jung-Hyun Byun, M.D.1, Myungsook Kim, Ph.D.1, Yangsoon Lee , M.D.2, Kyungwon Lee, M.D.1, and Yunsop Chong, Ph.D.1
1Department of Laboratory Medicine, Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea; 2Department of 
Laboratory Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Korea
Background: Anaerobic bacterial resistance trends may vary across regions or institutions. 
Regional susceptibility patterns are pivotal in the empirical treatment of anaerobic infec-
tions. We determined the antimicrobial resistance patterns of clinically important anaero-
bic bacteria, including recently named or renamed anaerobes. 
Methods: A total of 521 non-duplicated clinical isolates of anaerobic bacteria were col-
lected from a tertiary-care hospital in Korea between 2014 and 2016. Anaerobes were 
isolated from blood, body fluids, and abscess specimens. Each isolate was identified by 
conventional methods and by Bruker biotyper mass spectrometry (Bruker Daltonics, 
Leipzig, Germany) or VITEK matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (bioMérieux, Marcy-l’Étoile, France). Antimicrobial susceptibility was tested 
using the agar dilution method according to the CLSI guidelines. The following antimicro-
bials were tested: piperacillin-tazobactam, cefoxitin, cefotetan, imipenem, meropenem, 
clindamycin, moxifloxacin, chloramphenicol, tetracycline, and metronidazole. 
Results: Most Bacteroides fragilis isolates were susceptible to piperacillin-tazobactam, 
imipenem, and meropenem. The non-fragilis Bacteroides group (including B. intestinalis, 
B. nordii, B. pyogenes, B. stercoris, B. salyersiae, and B. cellulosilyticus) was resistant  to 
meropenem (14%) and cefotetan (71%), and Parabacteroides distasonis was resistant to 
imipenem (11%) and cefotetan (95%). Overall, the Prevotella and Fusobacterium isolates 
were more susceptible to antimicrobial agents than the B. fragilis group isolates. Anaero-
bic gram-positive cocci exhibited various resistance rates to tetracycline (6–86%). Clos-
tridioides difficile was highly resistant to penicillin, cefoxitin, imipenem, clindamycin, and 
moxifloxacin. 
Conclusions: Piperacillin-tazobactam, cefoxitin, and carbapenems are highly active 
β-lactam agents against most anaerobes, including recently named or renamed species. 
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INTRODUCTION
The prevalence of antibiotic resistance in anaerobes is increas-
ing, which impacts both antibiotic treatment and patient mortal-
ity [1]. Regional susceptibility patterns are pivotal in the empiri-
cal treatment of anaerobic infections. As the resistance trends 
of anaerobic bacteria may vary greatly, across regions or institu-
tions [2-4], antimicrobial susceptibility tests (ASTs) should be 
performed to assist with empirical antimicrobial treatment of an-
aerobic infections.
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The CLSI has stated that routine ASTs for anaerobes are not 
necessary, because antibiotic resistance is often predictable [5]. 
Therefore, we do not always perform ASTs; however, since 
1989, we have been performing periodic ASTs to investigate re-
sistance trends among clinical bacterial isolates [6-9].
Anaerobic gram-negative bacilli (GNB) are clinically important 
because they have high resistance rates relative to other anaer-
obic bacteria [10]. Recently, a related cluster of multidrug-resis-
tant Bacteroides fragilis isolates were recovered from several 
patients, which resulted in treatment failure in some cases [11, 
12]. Furthermore, a number of anaerobic species have recently 
been named or renamed. Parabacteroides distasonis and P. 
goldsteinii were reclassified from the genus Bacteroides; Allos-
cardovia omnicolens, Bulleidia extructa, Leptotrichia trevisanii, 
Alistipes finegoldii, and Alistipes onderdonkii were named in the 
2000s [13-18]. Moreover, AST data for infrequently isolated 
species are quite limited. Therefore, we collected rarely isolated 
anaerobic bacteria from clinical specimens and evaluated them 
using ASTs. In addition, we determined the antimicrobial resis-
tance patterns of clinically important anaerobic bacteria, includ-
ing recently named or renamed anaerobes.  
METHODS
Bacterial isolates
A total of 521 non-duplicated clinical anaerobic bacteria isolates 
were collected from a tertiary-care hospital (Severance Hospital, 
Seoul, Korea) between 2014 and 2016. Anaerobes were iso-
lated from blood, body fluids, and abscess specimens. Each 
isolate was identified by conventional methods, Bruker biotyper 
mass spectrometry (Bruker Daltonics, Leipzig, Germany), or VI-
TEK matrix-assisted laser desorption ionization time-of-flight 
mass spectrometry (bioMérieux, Marcy-l’Étoile, France). 
We tested a total of 230 gram-negative isolates, including 60 
Bacteroides fragilis, 68 non-fragilis Bacteroides spp., 29 Para-
bacteroides spp., 33 Prevotella spp., 19 Fusobacterium spp., 
10 other anaerobic GNB, and 11 Veillonella spp. Non-fragilis 
Bacteroides isolates were divided into two groups as follows: 
Group I included B. thetaiotaomicron, B. caccae, B. uniformis, 
B. vulgatus, and B. ovatus; Group II were recently classified, re-
named, or infrequently isolated including B. intestinalis, B. nor-
dii, B. pyogenes, B. stercoris, B. salyersiae, and B. cellulosilyti-
cus. A total of 291 gram-positive isolates were tested, including 
31 Finegoldia magna, 29 Parvimonas micra, 14 other gram-
positive cocci (GPC), 15 Clostridioides difficile, 27 Clostridium 
spp., 34 Actinomyces odontolyticus, 23 Actinomyces spp., 18 
Bifidobacterium spp., 38 Eggerthella lenta, 36 Lactobacillus spp., 
and 26 other gram-positive bacilli. 
ASTs
ASTs were conducted using the agar dilution method, and mini-
mum inhibitory concentrations (MICs) were interpreted accord-
ing to the CLSI guidelines [5, 19]. The medium used was Bru-
cella agar (Becton Dickinson, Cockeysville, MD, USA) supple-
mented with 5 µg/mL hemin, 1 µg/mL vitamin K1, and 5% laked 
sheep blood. The following antimicrobials were tested: penicillin 
(Sigma Aldrich, Yongin, Korea), piperacillin-tazobactam (Yuhan, 
Seoul, Korea), cefoxitin (Merck Sharp & Dohme, West Point, PA, 
USA), cefotetan (Daiichi Pharmaceutical, Tokyo, Japan), imipe-
nem and metronidazole (Choongwae, Seoul, Korea), clindamy-
cin (Korea Upjohn, Seoul, Korea), meropenem (Sumitomo, To-
kyo, Japan), moxifloxacin (Bayer Korea, Seoul, Korea), chloram-
phenicol (Chong Kun Dang, Seoul, Korea), and tetracycline (Sigma 
Aldrich). For the piperacillin and tazobactam combination, a 
constant concentration of tazobactam (4 µg/mL) was added. An 
inoculum of 105 colony forming units (CFUs) was applied with a 
Steers replicator (Craft Machine Inc., Woodline, PA, USA), and 
the plates were incubated in an anaerobic chamber (Forma Sci-
entific, Marietta, OH, USA) for 48 hours at 37°C. Quality control 
was tested with the following two organisms: B. fragilis ATCC 
25285 and B. thetaiotaomicron ATCC 29741. Double-disk po-
tentiation tests (DPTs) with dipicolinic acid were carried out on 
Brucella agar to screen for carbapenemase-producing B. fragilis 
group isolates [20]. 
RESULTS
Anaerobic gram-negative isolates
Most of the gram-negative isolates tested were susceptible to 
piperacillin-tazobactam, imipenem, and meropenem, as their 
resistance rates to these three antimicrobials were <7% (Table 1). 
Low frequencies of resistance to chloramphenicol and metroni-
dazole were observed for most of the anaerobic gram-negative 
bacterial isolates tested. 
High rates of resistance to penicillin (98–100%), cefotetan 
(12–71%), and clindamycin (38–69%) were noted for the B. 
fragilis group isolates. The resistance of B. fragilis isolates to ce-
fotetan was 12%; however, the non-fragilis Bacteroides Group II 
isolates showed high resistance to cefotetan (71%). Further-
more, Parabacteroides spp. (including P. distasonis), reclassi-
fied from the genus Bacteroides, showed very high resistance to 
cefotetan (95–100%). The resistance of B. fragilis and non-fra-
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Table 1. Antimicrobial susceptibility of 521 anaerobic bacterial isolates from 2014 to 2016
N of isolates and antimicrobial 
agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)*
S I R Range 50% 90% S I   R
Bacteroides fragilis (60)
   Penicillin ≤0.5 1 ≥2 4–>128 16 >128 0 0 100
   Piperacillin-tazobactam ≤32 64 ≥128 0.12–>128 1 4 95 0 5
   Cefoxitin ≤16 32 ≥64 4–64 8 32 82 12 7
   Cefotetan ≤16 32 ≥64 2–>128 8 64 75 13 12
   Imipenem ≤4 8 ≥16 ≤0.06–32 0.12 1 95 0 5
   Meropenem ≤4 8 ≥16 ≤0.06–>128 0.12 2 92 3 5
   Clindamycin ≤2 4 ≥8 ≤0.06–>128 1 >128 60 2 38
   Moxifloxacin ≤2 4 ≥8 ≤0.06–32 0.5 8 77 3 20
   Chloramphenicol ≤8 16 ≥32 4–8 4 8 100 0 0
   Metronidazole ≤8 16 ≥32 0.25–8 4 4 100 0 0
Non-fragilis Bacteroides group I (54)†
   Penicillin ≤0.5 1 ≥2 ≤0.06–>128 128 >128 2 0 98
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–>128 8 32 93 2 6
   Cefoxitin ≤16 32 ≥64 1–>128 16 32 57 35 7
   Cefotetan ≤16 32 ≥64 0.5–>128 64 >128 17 24 59
   Imipenem ≤4 8 ≥16 ≤0.06–32 0.5 2 94 4 2
   Meropenem ≤4 8 ≥16 ≤0.06–4 0.5 2 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06–>128 >128 >128 20 11 69
   Moxifloxacin ≤2 4 ≥8 ≤0.06–32 2 8 78 7 15
   Chloramphenicol ≤8 16 ≥32 2–8 8 8 100 0 0
   Metronidazole ≤8 16 ≥32 0.5–8 2 4 100 0 0
Non-fragilis Bacteroides group II (14)‡
   Penicillin ≤0.5 1 ≥2 16–>128 16 >128 0 0 100
   Piperacillin-tazobactam ≤32 64 ≥128 0.5–32 8 32 100 0 0
   Cefoxitin ≤16 32 ≥64 1–64 32 32 43 50 7
   Cefotetan ≤16 32 ≥64 4–>128 64 128 21 7 71
   Imipenem ≤4 8 ≥16 0.12–2 0.25 2 100 0 0
   Meropenem ≤4 8 ≥16 0.12–32 0.25 16 86 0 14
   Clindamycin ≤2 4 ≥8 0.5–>128 >128 >128 36 0 64
   Moxifloxacin ≤2 4 ≥8 0.5–64 1 16 79 0 21
   Chloramphenicol ≤8 16 ≥32 4–8 8 8 100 0 0
   Metronidazole ≤8 16 ≥32 2–4 2 4 100 0 0
Parabacteroides distasonis (19)
   Penicillin ≤0.5 1 ≥2 ≤0.06–>128 >128 >128 5 0 95
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–>128 32 >128 89 0 11
   Cefoxitin ≤16 32 ≥64 1–128 32 64 21 42 37
   Cefotetan ≤16 32 ≥64 1–>128 128 >128 5 0 95
   Imipenem ≤4 8 ≥16 ≤0.06–64 1 16 89 0 11
   Clindamycin ≤2 4 ≥8 ≤0.06–>128 >128 >128 5 16 79
(Continued to the next page)
Byun JH, et al.
Anaerobic resistance trends in Korea
https://doi.org/10.3343/alm.2019.39.2.190 www.annlabmed.org  193
N of isolates and antimicrobial 
agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)*
S I R Range 50% 90% S I   R
   Moxifloxacin ≤2 4 ≥8 0.12–32 0.5 16 79 0 21
   Chloramphenicol ≤8 16 ≥32 2–8 8 8 100 0 0
   Metronidazole ≤8 16 ≥32 0.5–4 2 4 100 0 0
Parabacteroides spp. (10)§
   Penicillin ≤0.5 1 ≥2 8–>128 >128 >128 0 0 100
   Piperacillin-tazobactam ≤32 64 ≥128 2–32 16 32 100 0 0
   Cefoxitin ≤16 32 ≥64 16–64 32 64 20 50 30
   Cefotetan ≤16 32 ≥64 64–>128 128 >128 0 0 100
   Imipenem ≤4 8 ≥16 1–4 1 4 100 0 0
   Clindamycin ≤2 4 ≥8 0.5–>128 >128 >128 20 0 80
   Moxifloxacin ≤2 4 ≥8 0.25–16 0.5 16 60 10 30
   Chloramphenicol ≤8 16 ≥32 4–8 8 8 100 0 0
   Metronidazole ≤8 16 ≥32 1–4 2 4 100 0 0
Prevotella spp. (33)ǁ
   Penicillin ≤0.5 1 ≥2 ≤0.06–>128 16 32 6 3 91
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–8 ≤0.06 ≤0.06 100 0 0
   Cefoxitin ≤16 32 ≥64 0.5–32 1 4 97 3 0
   Cefotetan ≤16 32 ≥64 0.5–64 2 32 88 9 3
   Imipenem ≤4 8 ≥16 ≤0.06–1 ≤0.06 ≤0.06 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06–>128 ≤0.06 >128 55 0 45
   Moxifloxacin ≤2 4 ≥8 0.12–64 0.5 4 70 21 9
   Chloramphenicol ≤8 16 ≥32 1–16 2 8 91 9 0
   Metronidazole ≤8 16 ≥32 0.12–32 1 8 91 6 3
Fusobacterium spp.(19)¶
   Penicillin ≤0.5 1 ≥2 ≤0.06–>128 0.25 4 79 5 16
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–8 2 4 100 0 0
   Cefoxitin ≤16 32 ≥64 0.12–16 4 8 100 0 0
   Cefotetan ≤16 32 ≥64 ≤0.06–32 2 4 95 5 0
   Imipenem ≤4 8 ≥16 ≤0.06–4 1 2 100 0 0
   Meropenem ≤4 8 ≥16 ≤0.06–2 ≤0.06 1 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06–128 2 16 58 21 21
   Moxifloxacin ≤2 4 ≥8 ≤0.06–128 4 8 42 47 11
   Chloramphenicol ≤8 16 ≥32 ≤0.06–2 2 2 100 0 0
   Metronidazole ≤8 16 ≥32 0.12–1 ≤0.06 1 100 0 0
Other gram-negative bacilli (10)**
   Penicillin ≤0.5 1 ≥2 ≤0.06–>128 1 16 30 30 40
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–>128 1 128 80 0 20
   Cefoxitin ≤16 32 ≥64 0.25–32 2 32 80 20 0
   Cefotetan ≤16 32 ≥64 0.5–32 2 4 90 10 0
   Imipenem ≤4 8 ≥16 ≤0.06–0.5 0.25 0.25 100 0 0
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N of isolates and antimicrobial 
agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)*
S I R Range 50% 90% S I   R
   Clindamycin ≤2 4 ≥8 ≤0.06–32 ≤0.06 4 90 0 10
   Moxifloxacin ≤2 4 ≥8 ≤0.06–16 0.5 16 50 10 40
   Chloramphenicol ≤8 16 ≥32 0.25–8 4 8 100 0 0
   Metronidazole ≤8 16 ≥32 ≤0.06–64 NA NA NA NA NA
Veillonella spp. (11)††
   Penicillin ≤0.5 1 ≥2 2–16 4 16 0 0 100
   Piperacillin-tazobactam ≤32 64 ≥128 4–128 16 32 91 0 9
   Cefoxitin ≤16 32 ≥64 2–8 4 8 100 0 0
   Cefotetan ≤16 32 ≥64 0.5–32 1 2 91 9 0
   Imipenem ≤4 8 ≥16 0.25–8 0.50 2 91 9 0
   Clindamycin ≤2 4 ≥8 ≤0.06–>128 ≤0.06 2 91 0 9
   Moxifloxacin ≤2 4 ≥8 ≤0.06–64 0.25 4 82 9 9
   Chloramphenicol ≤8 16 ≥32 0.5–2 2 2 100 0 0
   Metronidazole ≤8 16 ≥32 2–32 8 32 73 0 27
Finegoldia magna (31)
   Penicillin ≤0.5 1 ≥2 ≤0.06–0.12 ≤0.06 ≤0.06 100 0 0
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–0.12 ≤0.06 ≤0.06 100 0 0
   Cefoxitin ≤16 32 ≥64 0.25–4 0.5 2 100 0 0
   Cefotetan ≤16 32 ≥64 0.12–4 0.25 2 100 0 0
   Imipenem ≤4 8 ≥16 ≤0.06–≤0.06 ≤0.06 ≤0.06 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06–64 ≤0.06 0.5 94 3 3
   Moxifloxacin ≤2 4 ≥8 0.12–8 0.25 0.5 94 0 6
   Metronidazole ≤8 16 ≥32 0.12–8 1 1 100 0 0
   Tetracycline ≤4 8 ≥16 ≤0.06–16 0.25 4 94 0 6
Parvimonas micra (29)
   Penicillin ≤0.5 1 ≥2 ≤0.06–0.25 0.12 0.25 100 0 0
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–2 0.12 0.25 100 0 0
   Cefoxitin ≤16 32 ≥64 0.25–4 0.5 1 100 0 0
   Cefotetan ≤16 32 ≥64 0.5–2 1 2 100 0 0
   Imipenem ≤4 8 ≥16 ≤0.06–0.25 ≤0.06 0.12 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06–128 1 128 76 0 24
   Moxifloxacin ≤2 4 ≥8 ≤0.06–32 2 32 52 0 48
   Metronidazole ≤8 16 ≥32 0.5–4 1 2 100 0 0
   Tetracycline ≤4 8 ≥16 1–64 16 32 45 0 55
Other gram-positive cocci (14)i
   Penicillin ≤0.5 1 ≥2 ≤0.06–8 0.12 8 64 0 36
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–16 0.25 16 100 0 0
   Cefoxitin ≤16 32 ≥64 ≤0.06–16 0.50 16 100 0 0
   Cefotetan ≤16 32 ≥64 0.25–128 4 128 50 7 43
   Imipenem ≤4 8 ≥16 ≤0.06–4 0.25 4 100 0 0
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N of isolates and antimicrobial 
agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)*
S I R Range 50% 90% S I   R
   Clindamycin ≤2 4 ≥8 ≤0.06–128 0.25 128 50 7 43
   Moxifloxacin ≤2 4 ≥8 0.12–16 2 8 64 7 29
   Metronidazole ≤8 16 ≥32 0.5–8 2 2 100 0 0
   Tetracycline ≤4 8 ≥16 0.25–64 32 64 14 0 86
Clostridioides difficile (15)
   Penicillin ≤0.5 1 ≥2 2–4 2 4 0 0 100
   Piperacillin-tazobactam ≤32 64 ≥128 4–16 16 16 100 0 0
   Cefoxitin ≤16 32 ≥64 128–>128 128 >128 0 0 100
   Cefotetan ≤16 32 ≥64 16–64 32 64 20 40 40
   Imipenem ≤4 8 ≥16 4–64 16 32 7 0 93
   Clindamycin ≤2 4 ≥8 1–>128 16 >128 7 27 67
   Moxifloxacin ≤2 4 ≥8 1–32 16 32 47 0 53
   Metronidazole ≤8 16 ≥32 0.5–4 2 2 100 0 0
   Tetracycline ≤4 8 ≥16 0.25–32 0.5 32 60 13 27
Clostridium spp. (27)j
   Penicillin ≤0.5 1 ≥2 ≤0.06–2 0.5 2 74 15 11
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–32 0.5 16 100 0 0
   Cefoxitin ≤16 32 ≥64 0.25–128 2 64 85 4 11
   Cefotetan ≤16 32 ≥64 0.25–>128 4 >128 78 4 19
   Imipenem ≤4 8 ≥16 0.25–8 1 4 96 4 0
   Clindamycin ≤2 4 ≥8 ≤0.06–>128 1 >128 63 4 33
   Moxifloxacin ≤2 4 ≥8 0.12–128 1 32 74 7 19
   Metronidazole ≤8 16 ≥32 0.25–64 2 8 93 0 7
   Tetracycline ≤4 8 ≥16 0.12–64 16 64 26 11 63
Actinomyces odontolyticus (34)
   Penicillin ≤0.5 1 ≥2 ≤0.06–8 0.5 8 53 18 29
   Piperacillin-tazobactam ≤32 64 ≥128 0.5–64 4 32 91 9 0
   Cefoxitin ≤16 32 ≥64 ≤0.06–32 1 16 97 3 0
   Cefotetan ≤16 32 ≥64 0.5–128 8 128 65 12 24
   Imipenem ≤4 8 ≥16 ≤0.06–8 0.5 2 97 3 0
   Clindamycin ≤2 4 ≥8 ≤0.06–>128 0.5 >128 62 0 38
   Moxifloxacin ≤2 4 ≥8 2–32 2 2 97 0 3
   Metronidazole ≤8 16 ≥32 8–>128 32 >128 6 29 65
   Tetracycline ≤4 8 ≥16 2–32 2 16 79 0 21
Actinomyces spp. (23)ǁǁ
   Penicillin ≤0.5 1 ≥2 ≤0.06–0.5 0.12 0.12 100 0 0
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–1 0.5 1 100 0 0
   Cefoxitin ≤16 32 ≥64 0.12–1 0.25 1 100 0 0
   Cefotetan ≤16 32 ≥64 ≤0.06–4 0.5 4 100 0 0
   Imipenem ≤4 8 ≥16 ≤0.06–0.25 ≤0.06 0.25 100 0 0
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N of isolates and antimicrobial 
agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)*
S I R Range 50% 90% S I   R
   Clindamycin ≤2 4 ≥8 ≤0.06–>128 0.25 >128 78 0 22
   Moxifloxacin ≤2 4 ≥8 0.5–2 1 2 100 0 0
   Metronidazole ≤8 16 ≥32 32–>128 >128 >128 0 0 100
   Tetracycline ≤4 8 ≥16 0.5–64 1 32 78 0 22
Bifidobacterium spp. (18)¶¶
   Penicillin ≤0.5 1 ≥2 ≤0.06–4 0.12 4 72 11 17
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–32 0.12 16 100 0 0
   Cefoxitin ≤16 32 ≥64 ≤0.06–64 1 64 83 0 17
   Cefotetan ≤16 32 ≥64 0.25–>128 2 >128 72 0 28
   Imipenem ≤4 8 ≥16 ≤0.06–1 0.12 0.5 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06–>128 0.5 >128 72 0 28
   Moxifloxacin ≤2 4 ≥8 ≤0.06–16 1 4 89 6 6
   Metronidazole ≤8 16 ≥32 0.5–>128 8 >128 67 11 22
   Tetracycline ≤4 8 ≥16 2–128 2 16 83 6 11
Eggerthella lenta (38)
   Penicillin ≤0.5 1 ≥2 0.5–2 1 2 8 45 47
   Piperacillin-tazobactam ≤32 64 ≥128 16–32 16 32 100 0 0
   Cefoxitin ≤16 32 ≥64 2–32 8 16 95 5 0
   Cefotetan ≤16 32 ≥64 32–>128 128 >128 0 5 95
   Imipenem ≤4 8 ≥16 0.5–0.5 0.5 1 100 0 0
   Clindamycin ≤2 4 ≥8 0.12–0.5 0.5 >128 63 0 37
   Moxifloxacin ≤2 4 ≥8 0.12–4 4 64 47 21 32
   Metronidazole ≤8 16 ≥32 0.5–1 1 1 100 0 0
   Tetracycline ≤4 8 ≥16 0.5–32 32 64 37 3 61
Lactobacillus spp. (36)***
   Penicillin ≤0.5 1 ≥2 ≤0.06–>128 0.5 2 56 22 22
   Piperacillin-tazobactam ≤32 64 ≥128 0.5–>128 4 8 94 0 6
   Cefoxitin ≤16 32 ≥64 4–>128 >128 >128 17 3 81
   Cefotetan ≤16 32 ≥64 8–>128 >128 >128 3 0 97
   Imipenem ≤4 8 ≥16 ≤0.06–16 0.25 8 86 11 3
   Clindamycin ≤2 4 ≥8 ≤0.06–1 0.12 0.5 100 0 0
   Moxifloxacin ≤2 4 ≥8 0.25–4 1 2 94 6 0
   Metronidazole ≤8 16 ≥32 32–>128 >128 >128 0 0 100
   Tetracycline ≤4 8 ≥16 0.5–>128 8 32 44 33 22
Other gram-positive bacilli (26)†††
   Penicillin ≤0.5 1 ≥2 ≤0.06–4 0.12 0.25 96 0 4
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06–2 0.12 2 100 0 0
   Cefoxitin ≤16 32 ≥64 ≤0.06–16 1 4 100 0 0
   Cefotetan ≤16 32 ≥64 ≤0.06–32 2 8 96 4 0
   Imipenem ≤4 8 ≥16 ≤0.06–0.5 ≤0.06 0.12 100 0 0
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Table 1. Continued
Byun JH, et al.
Anaerobic resistance trends in Korea
https://doi.org/10.3343/alm.2019.39.2.190 www.annlabmed.org  197
N of isolates and antimicrobial 
agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)*
S I R Range 50% 90% S I   R
   Clindamycin ≤2 4 ≥8 ≤0.06–64 ≤0.06 4 85 8   8
   Moxifloxacin ≤2 4 ≥8 ≤0.06–4 0.25 1 96 4   0
   Metronidazole ≤8 16 ≥32 0.25–>128 8 >128 60 0 40
   Tetracycline ≤4 8 ≥16 0.25–8 2 8 72 28   0
*Susceptibility was determined by breakpoint according to the CLSI M100 27th edition [19]; †Bacteroides thetaiotaomicron (N=26), B. caccae (N=9), B. 
uniformis (N=7), B. vulgatus (N=7), B. ovatus (N=5); ‡B. intestinalis (N=4), B. nordii (N =3), B. pyogenes (N=2), B. stercoris (N=2), B. salyersiae (N=2), 
B. cellulosilyticus (N=1); §Parabacteroides goldsteinii (N=5), P. johnsonii (N=2), P. merdae (N=2), P. faecis (N=1); ǁPrevotella buccae (N=15), P. bivia 
(N=10), P. nigrescens (N=3), P. buccalis (N=1), P. disiens (N=1), P. intermedia (N=1), P. melaninogenica (N=1), P. oralis (N=1); ¶Fusobacterium vari-
um (N=14), F. mortiferum (N=2), F. ulcerans (N=2), F. nucleatum (N=1); **Dialister pneumosintes (N=2), Leptotrichia trevisanii (N=2), L. buccalis 
(N=1), Alistipes finegoldii (N=1), A. onderdonkii (N=1), Bilophila sp. (N=1), Megamonas sp. (N=1), Sutterella wadsworthensis (N=1); ††Veillonella parvu-
la (N=9), V. atypica (N=1), V. dispar (N=1); ‡‡Peptoniphilus anaerobius (N=3), P. asaccharolyticus (N=2), P. gorbachii (N=2), P. harei (N=1), Anaero-
coccus vaginalis (N=2), A. murdochii (N=1), A. prevotii (N=1), Ruminococcus gnavus (N=2); §§Clostridium bifermentans (N=3), C. hathewayi (N=3), C. 
innocuum (N=3), C. paraputrificum (N=3), C. perfringens (N=3), C. butyricum (N=2), C. ramosum (N=2), C. sordellii (N=2), C. tertium (N=2), C. ca-
daveris (N=1), C. scindens (N=1), C. sporogenes (N=1), C. bolteae (N=1); ǁǁActinomyces oris (N=7), A. turicensis (N=7), A. neuii (N=4), A. viscosus (N 
=2), A. europaeus (N=1), A. meyeri (N=1), A. naeslundii (N=1); ¶¶Bifidobacterium dentium (N=5), B. longum (N=5), B. breve (N=4), B. bifidum (N=2), 
B. pseudocatenulatum (N=1), B. thermophilum (N=1); ***Lactobacillus paracasei (N=5), L. rhamnosus (N=5), L. sakei (N=5), L. salivarius (N=4), L. 
fermentum (N=3), L. mucosae (N=3), L. crispatus (N=2), L. gasseri (N=2), L. plantarum (N=2), L. reuteri (N=2), L. curvatus (N=1), L. harbinensis (N=1), 
L. sporogenes (N=1); †††Atopobium parvulum (N=7), A. rimae (N=2), Propionibacterium acnes (N=5), P. avidum (N=1), P. lymphophilum (N=1), Ac-
tinotignum schaalii (N=2), Alloscardovia omnicolens (N=2), Bulleidia extructa (N=2), Collinsella aerofaciens (N=2), Flavonifractor plautii (N=1), Slackia 
exigua (N=1).
Abbreviations: S, susceptible; I, intermediate; R, resistant; MIC, minimum inhibitory concentration. 
Table 1. Continued
gilis Bacteroides group I and II isolates to moxifloxacin was 20% 
and 16%, respectively. Overall, Parabacteroides spp. exhibited 
higher resistance rates relative to B. fragilis spp., especially for 
clindamycin (79%) and moxifloxacin (24%). Bacteroides fragilis 
exhibited imipenem and meropenem-resistance rates of 5%. 
Non-fragilis Bacteroides Group I showed resistance to only imi-
penem (2%), while non-fragilis Bacteroides Group II showed re-
sistance to only meropenem (14%). The meropenem MIC re-
quired to decrease growth by 90% (MIC90 =16 µg/mL) for non-
fragilis Bacteroides Group II was higher than that for B. fragilis 
and non-fragilis Bacteroides Group I (MIC90 =2 µg/mL). Four 
carbapenem-non-susceptible B. fragilis isolates showed positive 
results on DPTs, whereas eight carbapenem-non-susceptible 
non-fragilis Bacteroides isolates (including B. thetaiotaomicron, 
B. intestinalis, B. nordii, P. distasonis, and P. merdae) showed 
negative results. 
Overall, Prevotella and Fusobacterium isolates were more 
susceptible to antimicrobial agents than B. fragilis group iso-
lates. Interestingly, one Prevotella spp. isolate was resistant to 
metronidazole (3%). The other anaerobic GNB were susceptible 
to most of the antibiotics tested. However, all Leptotrichia iso-
lates were resistant to moxifloxacin (MIC=8–16 µg/mL). Me-
gamonas spp. and Sutterella wadsworthensis were resistant to 
piperacillin-tazobactam (MIC ≥128 µg/mL), and three Veillon-
ella isolates (27%) were resistant to metronidazole. 
Anaerobic gram-positive isolates  
A total of 74 anaerobic GPC, including 31 Finegoldia magna 
and 29 Parvimonas micra, exhibited various resistance rates to 
moxifloxacin (6–48%), clindamycin (3–43%), and tetracycline 
(6–86%). Overall, F. magna isolates were more susceptible than 
other GPC isolates, with a resistance rate <6% to all antimicro-
bials tested (Table 1). The resistance rate of the other GPC iso-
lates to penicillin was 36%, with all species identified as Pepto-
niphilus. 
C. difficile showed high resistance to penicillin (100%), cefox-
itin (100%), imipenem (93%), and moxifloxacin (53%). All non-
odontolyticus Actinomyces and Lactobacillus isolates and 65% 
of Actinomyces odontolyticus isolates were resistant to metroni-
dazole. All non-odontolyticus Actinomyces isolates were suscep-
tible to the other antimicrobial agents tested, except for clindamy-
cin (22% resistance) and tetracycline (22% resistance). E. lenta 
demonstrated high resistance rates to penicillin (47%), cefotetan 
(95%), tetracycline (61%), and moxifloxacin (32%). Other GPB, 
such as Actinotignum, Alloscardovia, Bulleidia, Collinsella, Fla-
vonifractor, and Slackia, were generally susceptible to all agents 
tested, except for metronidazole.
DISCUSSION
The Bacteroides fragilis group of anaerobic gram-negative iso-
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lates (including Parabacteroides spp.) are the most clinically 
significant anaerobes because they are commonly isolated from 
clinical specimens and show greater virulence and resistance 
than most other anaerobes [10]. The resistance of B. fragilis 
isolates to cefotetan remained low for several years: 14% in 
1997–2004 [8], 14% in 2007–2008 [7], 13% in 2009–2012 
[9], and 12% in 2014–2016. 
The resistance of B. fragilis isolates to moxifloxacin has 
steadily increased over the past 11 years, from 11% in 2007–
2008 to 20% in 2014–2016. The current values are similar to 
those observed in 2010–2012 in the USA (19.1%) [21]. The re-
sistance to moxifloxacin among non-fragilis Bacteroides group 
species has not increased; the rates have ranged from 18% in 
2007–2008 to 16% in 2014–2016 [7]. This may reflect the fact 
that the B. fragilis group includes former members of the group 
previously reclassified as Parabacteroides spp. [7]. Parabacte-
roides spp. had a higher resistance rate to clindamycin and a 
lower resistance rate to moxifloxacin compared with isolates in 
the USA (50% and 44%, respectively) [21].
We observed that non-fragilis Bacteroides Group II had higher 
resistance rates to meropenem than imipenem, while non-fragi-
lis Bacteroides Group I demonstrated the opposite pattern. Such 
patterns have been previously reported by Sóki et al. [22]; how-
ever, they did not include the carbapenem resistance patterns 
of non-fragilis Bacteroides Group II.
Prevotella spp. were highly susceptible to most antimicrobials 
except penicillin and clindamycin. The resistance rates to clin-
damycin remained high, at 45%, for Prevotella spp., compared 
with 50% in 2007–2008 [7]. Only one Prevotella spp. isolate 
was resistant to metronidazole. This represents an even lower 
rate of resistance than that reported in Greece (8%) [23]. The 
Veillonella resistance rate to metronidazole was 27%, higher 
than that reported in the USA (11%) [4]. 
The anaerobic GPC isolates exhibited various rates of resis-
tance to penicillin, clindamycin, and metronidazole [2]. How-
ever, the resistance rate of GPC to clindamycin, moxifloxacin, 
and tetracycline varied across species. The resistance of C. dif-
ficile to imipenem has rapidly increased over the past years, 
from 8% in 2007–2008 to 93% in 2014–2016 [7]. There is a 
general assumption that resistance varies with ribotype; Lee et al. 
[24] showed that ribotypes 017 and 018 have high MICs for 
moxifloxacin and imipenem, compared with ribotype 001. Met-
ronidazole-resistant isolates were common among Actinomyces 
and Lactobacillus spp. A study in Argentina showed that all Ac-
tinomyces spp. were susceptible to penicillin, and 21.2% were 
resistant to clindamycin [25]. E. lenta has been commonly as-
sociated with gastrointestinal infections; its overall mortality is 
significant, ranging from 36% to 48% [26, 27]. The E. lenta re-
sistance rates we observed were much higher than those in 
Australia (0% for penicillin and 12% for moxifloxacin) [26]. 
The limitations of this study were the small number of re-
named and reclassified bacteria and bacterial isolates collected. 
Further, it was a single-center, retrospective study. 
In conclusion, piperacillin-tazobactam, cefoxitin, and car-
bapenems were β-lactam agents highly active against most of 
the anaerobic bacteria we tested. However, recently renamed 
non-fragilis Bacteroides group isolates showed resistance to 
meropenem (14%). These data suggest the importance of on-
going surveillance to provide clinically relevant information to 
clinicians for the empirical management of infections caused by 
anaerobic organisms. Continuous monitoring is necessary to 
detect changes in antimicrobial resistance patterns.
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